Tradestie Institutional Equity Comparison Engine
CVM vs CRIS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CVM Overall Edge
CVM Captures Institutional Edge (3โ1 Pillars ยท 8โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cel-Sci Corporation (CVM) driven by superior Valuation, Growth & Margin, Momentum & Technical while CRIS counters with relative strength in Options & Structure. Fundamentally, CVM trades at 23.0x Forward P/E with 0.0% operating margin (-62.7% YoY revenue) versus CRIS at N/M Forward P/E and -833.4% operating margin (-66.0% YoY). In options structure, CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against CRIS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
CVM
CVM 23.0x vs CRIS N/M Fwd P/E
Growth & Margin Winner
CVM
Op Margin 0.0% vs -833.4% ยท YoY -62.7% vs -66.0%
Momentum & Technical Winner
CVM
1Y -77.5% vs -61.0% ยท 52W Pos 10% vs 4%
Options & Structure Winner
CRIS
BREAKDOWN (N/A IV) vs UNCLASSIFIED (N/A IV)
CVM
NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap
$20.9M
1M Return
-11.17%
1Y Return
-77.48%
Forward P/E
23.0x
Unified AI Score
56.6 / 100
HOLD
Tech 60.0
Fund 54.0
Flow 50.0
Mom 60.0
CRIS
NASDAQ
Curis Inc
Biological Products, (No Disgnostic Substances)
$0.44
-1.07% 1D
Market Cap
$3.8M
1M Return
+8.14%
1Y Return
-61.04%
Forward P/E
N/M
Unified AI Score
38.7 / 100
SELL
Tech 15.0
Fund 41.0
Flow 50.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CVM -77.48%
CRIS -61.04%
Spread: +9.08 pp (CRIS Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CVM Revenue | CRIS Revenue | CVM Op. Margin | CRIS Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $10M | N/A | -281.3% | CRIS |
| FY2019 | N/A | $10M | N/A | -243.5% | CRIS |
| FY2020 | N/A | $10M | N/A | -229.8% | CRIS |
| FY2021 | N/A | $10M | N/A | -395.0% | CRIS |
| FY2022 | N/A | $10M | N/A | -521.7% | CRIS |
| FY2023 | N/A | $10M | N/A | -482.2% | CRIS |
| FY2024 | N/A | $10M | N/A | -408.3% | CRIS |
| FY2025 | N/A | $10M | N/A | -60.5% | CRIS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CVM | CRIS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $20.9M | $3.8M | Larger Scale | CVM |
| Trailing P/E Ratio Valuation | 23.0x | 0.4x | Lower Multiple | CRIS |
| Forward P/E Ratio Valuation | 23.0x | N/M | Lower Multiple | CVM |
| Revenue Growth (YoY) Growth | -62.7% | -66.0% | Higher Growth | CVM |
| Operating Margin (TTM) Profitability | 0.0% | -833.4% | Higher Margin | CVM |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -252.5% | -693.9% | Higher ROE | CVM |
| 52-Week Range Position Momentum | 10% ($1โ$8) | 4% ($0โ$7) | Stronger Trend | CVM |
| Beta / 30D Volatility Risk Regime | 0.65ฮฒ ยท 120% Vol | 11.40ฮฒ ยท 269% Vol | Lower Realized Risk | CVM |
| Unified Institutional Score Composite Signal | 56.6 / 100 (HOLD) | 38.7 / 100 (SELL) | Higher Composite | CVM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CVM vs CRIS Buy Guide
CVM
BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CRIS
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CVM nor CRIS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.